ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q3Scopus Q2SCImago #7,934Hybrid

Immunopharmacology and Immunotoxicology

Acronym:lipi
•
Abbreviation (ISO):Immunopharmacol. Immunotoxicol
•
Identifier (ISSN):0892-3973(Print)/1532-2513(Online)
•
Publisher:Informa Healthcare
Clarivate IF (2026)
3.1↑ +0.1
Journal Impact Factor
IF Trend↓
WoS Quartile
Q3
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Immunopharmacology and Immunotoxicology

WoS Q3
12452.0220182.0920192.3520202.7320213.7120223.320232.92024320253.12026
Annual Impact Factor Metric
Current (2026):3.1
Scopus SJR & RankScopus Q2
0.723
#7,934

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
67

67 papers with at least that number of citations each

WoS: SCIE / JCRQ3
Self-Citation Rate0%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
90articles/year
1.83% Gold OA•92.48% Original Research

Aims & Scope

The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal. The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome. With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more. Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).

Topics Covered (Recognized by AI)
Medicine98.8%Biology98.6%Genetics89.9%Internal medicine88.7%Chemistry87.2%Immunology84.3%Biochemistry81.6%Endocrinology54.7%Immune system43.8%Pharmacology42.4%In vitro41.1%Organic chemistry37.4%Pathology31.9%Cell biology31%Physics24.5%Inflammation24.1%Antigen22.8%Gene22.4%Receptor21.9%Psychology21.4%Antibody20.2%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

IMMUNOLOGY

Q3
Rank108/183
IndexSCIE
JCRSCIE2026

PHARMACOLOGY & PHARMACY

Q2
Rank163/356
IndexSCIE
JCRSCIE2026

TOXICOLOGY

Q2
Rank52/106
IndexSCIE
JCISCIE2026

IMMUNOLOGY

Q2
Rank68/183
IndexSCIE
JCISCIE2026

PHARMACOLOGY & PHARMACY

Q2
Rank113/356
IndexSCIE
JCISCIE2026

TOXICOLOGY

Q2
Rank39/106
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF3.1
Articles / Year75
Total Citations21
2025
IF3
Articles / Year83
Total Citations191
2024
IF2.9
Articles / Year78
Total Citations379
2023
IF3.3
Articles / Year64
Total Citations525
2022
IF3.712
Articles / Year140
Total Citations1,565

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #7,934Scopus Q2SCImago Profile
Scopus Coverage:1978-2026
Scopus Broad Areas:Immunology and MicrobiologyMedicinePharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q2
0.723

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2
Citations / Doc (2 years)
2.85

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,093 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations846
3-Year Documents277
Citable Documents275

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate46.4%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Medicine (miscellaneous)Q2
PharmacologyQ2
ToxicologyQ2
ImmunologyQ3
Immunology and AllergyQ3
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
3区 (Zone 3)Medicine
Minor Category (Specific Field):
3区IMMUNOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Immunopharmacology and Immunotoxicology (acronym: lipi, abbr: Immunopharmacol. Immunotoxicol, ISSN: 0892-3973) is a peer-reviewed international scholarly journal in the field of Medicine, published by Informa Healthcare in United States. The periodical holds a Journal Impact Factor (JIF) of 3.10, ranking in quartile Q3 of Web of Science (SCIE), a Scopus SJR indicator of 0.723 (Q2), an H-index of 67.

The journal enforces rigorous peer evaluation with a publication frequency of Quarterly, an annual output of approximately 90 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,093 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Informa Healthcare
Publication Language
English
Frequency
Quarterly
Indexing & Databases
SCIEScopusPubMed
Editorial Address
TAYLOR & FRANCIS INC, 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, USA, PA, 19106

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 92101923-b3a4-4bc9-a715-58ed826d358e
Database Updated: 2026-09-30